Regarding newer agents, evidence from phase 2 trials indicates that the triple agonist retatrutide (GLP-1R/GIPR/GCGR) can achieve unprecedented weight loss of up to 24.4% (Jastreboff et al., 2023)
Valuation models that incorporate PBM specialty drug margin as a durable competitive moat are increasingly wrong
You can do the same thing with GIP, GCG and peptide tyrosine tyrosine, which also play a role in appetite suppression
Weight loss injections dont directly damage the kidneys, but they can lead to acute kidney injury (AKI) through secondary dehydration
and (b) an endophenotype class of Long COVID patients (31.7%) who show simultaneously severe abnormalities in SpO2 and PBT during acute COVID-19, and an increased OSTOX/ANTIOX ratio, CRP and increased total HAMD, HAMA and FF total and subdomain scores during Long COVID
doi:10.1007/s00394-020-02233-0